Vaccitech Announces Closing of $110.5 Million Initial Public Offering

OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the closing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS. The gross proceeds from the offering were approximately $110.5 million. Vaccitech’s ordinary shares began trading on the Nasdaq Global Market in the U.S. under the ticker symbol “VACC” on April 30, 2021. All ADSs sold in the offering were offered by Vaccitech.

Read full release here